- Home
- / Ayala Pharmaceuticals
Ayala Pharmaceuticals
Stock Price
$0.5
2023-01-27
Market Capitalization
$7.4 M
2023-01-27
Revenue
$692 K
FY, 2022
Ayala Pharmaceuticals Summary
Company Summary
- Overview
- Ayala Pharmaceuticals is a clinical-stage biopharmaceutical company developing medicines for cancers that are genetically defined. The company offers AL101 and AL102 gamma-secretase inhibitors, with clinical and nonclinical studies underway in both solid tumors (AL101) and hematologic malignancies (AL102).
- Type
- Public
- Status
- Active
- Founded
- 2017
- HQ
- Wilmington, DE, US | view all locations
- Website
- https://www.ayalapharma.com/
- Cybersecurity rating
Table of Contents
Key People
Gary Gordon, Chief Medical Officer
Dana Gelbaum, Chief Business Officer
David Caron, VP CMC
LocationsView all
3 locations detected
Wilmington, DE HQ
United States
1205 N Orange St
Wilmington, DE
United States
1313 N Market St #5100
Rehovot, Center District
Israel
Prof. Hillel ve-Khanan Oppenheimer St 4
Ayala Pharmaceuticals Financials
Summary Financials
- Revenue (FY, 2022)
- $692.0K
- Gross profit (FY, 2022)
- $90.0K
- Net income (FY, 2022)
- ($38.0M)
- Cash (FY, 2022)
- $2.4M
- EBIT (FY, 2022)
- ($37.5M)
- Enterprise value
- $6.8M